OraSure Technologies, Inc. (NASDAQ:OSUR) Files An 8-K Regulation FD Disclosure
Item7.01 Regulation FD Disclosure.
On November29, 2016, OraSure Technologies, Inc. (the Company)
will host an Analyst Day meeting in New York City, New York, at
the NASDAQ MarketSite at Times Square. At the meeting, the
Companys senior executive team will make presentations to
analysts using slides containing the information attached to this
Current Report on Form 8-K as Exhibit 99.1. The fact that these
presentation materials are being furnished should not be deemed
an admission as to the materiality of any information contained
therein. The information contained in the slides is summary
information that is intended to be considered in the context of
the Companys Securities and Exchange Commission filings and other
public announcements that the Company has made or may make, by
press release or otherwise, from time to time. The Company
undertakes no duty or obligation to publicly update or revise the
information contained in this Current Report.
This information shall not be deemed filed for purposes of
Section18 of the Securities Exchange Act of 1934 or otherwise
subject to the liabilities of that section, nor shall such
information and Exhibit be deemed incorporated by reference in
any filing under the Securities Act of 1933, except as shall be
expressly set forth by specific reference in such a filing.
Item9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit Number |
Description |
|
| 99.1 |
Management presentation to be used at the OraSure Technologies, Inc. Analyst Day on November 29, 2016. |
About OraSure Technologies, Inc. (NASDAQ:OSUR)
OraSure Technologies, Inc. (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The Company also manufactures and sells medical devices used for the removal of benign skin lesions by cryosurgery or freezing. Its diagnostic products include tests, such as OraQuick Rapid HIV Test, OraQuick In-Home HIV Test, OraQuick HIV Self-Test, OraQuick HCV Rapid Antibody Test, OraQuick Ebola Rapid Antigen Test, OraSure QuickFlu Rapid Flu A&B Test, OraSure Collection Device, Molecular Collection Systems, Cryosurgical Systems (Skin Lesion Removal Products), Immunoassay Tests and Reagents, Western blot HIV-1 Confirmatory Test and Q.E.D. Saliva Alcohol Test. Its products are sold in the United States and internationally to clinical laboratories and hospitals. OraSure Technologies, Inc. (NASDAQ:OSUR) Recent Trading Information
OraSure Technologies, Inc. (NASDAQ:OSUR) closed its last trading session down -0.49 at 8.44 with 479,707 shares trading hands.
